These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

927 related articles for article (PubMed ID: 26256826)

  • 1. Analysis of JAK2V617F mutation in Jordanian patients with myeloproliferative neoplasms.
    Jaradat SA; Khasawneh R; Kamal N; Matalka I; Al-Bishtawi M; Al-Sweedan S; Ayesh MH
    Hematol Oncol Stem Cell Ther; 2015 Dec; 8(4):160-6. PubMed ID: 26256826
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
    Iványi JL; Marton E; Plander M
    Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid identification of heterozygous or homozygous JAK2(V617F) mutations in myeloproliferative neoplasms using melting curve analysis.
    Ho CL; Wu YY; Hung HM; Chang PY; Kao WY; Chen YC; Chao TY
    J Formos Med Assoc; 2012 Jan; 111(1):34-40. PubMed ID: 22333011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing concepts of diagnostic criteria of myeloproliferative disorders and the molecular etiology and classification of myeloproliferative neoplasms: from Dameshek 1950 to Vainchenker 2005 and beyond.
    Michiels JJ; Berneman Z; Schroyens W; De Raeve H
    Acta Haematol; 2015; 133(1):36-51. PubMed ID: 25116092
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [JAK2 exon 12 mutations in patients with Philadelphia (Ph) chromosome-negative myeloproliferative neoplasms].
    Wang JY; Ai XF; Xu JQ; Li QH; Xu ZF; Qin TJ; Zang Y; Xiao ZJ
    Zhonghua Xue Ye Xue Za Zhi; 2012 Sep; 33(9):705-9. PubMed ID: 23336221
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JAK2 V617F mutation status of 232 patients diagnosed with chronic myeloproliferative neoplasms.
    Payzin KB; Savasoglu K; Alacacioglu I; Ozdemirkiran F; Mutlu BB; Bener S; Calli AO; Kucukzeybek BB; Aksun S
    Clin Lymphoma Myeloma Leuk; 2014 Dec; 14(6):525-33. PubMed ID: 24811089
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between thromboembolic events and the JAK2 V617F mutation in myeloproliferative neoplasms.
    Takata Y; Seki R; Kanajii T; Nohara M; Koteda S; Kawaguchi K; Nomura K; Nakamura T; Morishige S; Oku E; Osaki K; Hashiguchi E; Mouri F; Yoshimoto K; Nagafuji K; Okamura T
    Kurume Med J; 2014; 60(3-4):89-97. PubMed ID: 24858412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders.
    Larsen TS; Christensen JH; Hasselbalch HC; Pallisgaard N
    Br J Haematol; 2007 Mar; 136(5):745-51. PubMed ID: 17313377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The analysis of JAK2 and MPL mutations and JAK2 single nucleotide polymorphisms in MPN patients by MassARRAY assay.
    Zhang SJ; Qiu HX; Li JY; Shi JY; Xu W
    Int J Lab Hematol; 2010 Aug; 32(4):381-6. PubMed ID: 20331763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.
    Malysz J; Crisan D
    Ann Clin Lab Sci; 2009; 39(4):345-50. PubMed ID: 19880761
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A quantitative assay for JAK2 mutation in 135 patients with chronic myeloproliferative neoplasms].
    Chao HY; Shen YM; Zhang R; Feng YF; Cen JN; Yao L; Shen HJ; Zhu ZL; Xue YQ
    Zhonghua Xue Ye Xue Za Zhi; 2009 May; 30(5):321-5. PubMed ID: 19799128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
    Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
    Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population.
    Nielsen C; Birgens HS; Nordestgaard BG; Bojesen SE
    Br J Haematol; 2013 Jan; 160(1):70-9. PubMed ID: 23116358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms.
    Benati M; Montagnana M; Danese E; De Matteis G; Veneri D; Paviati E; Guidi GC
    Clin Chem Lab Med; 2015 Jun; 53(7):1005-11. PubMed ID: 25527813
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BCR-ABL negative myeloproliferative neoplasia: a review of involved molecular mechanisms.
    Koopmans SM; Schouten HC; van Marion AM
    Histol Histopathol; 2015 Feb; 30(2):151-61. PubMed ID: 25196073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
    Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Our experience with detection of JAK2 mutations in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative disorders].
    Burjanivová T; Marcinek J; Minárik G; Lasabová Z; Szépe P; Balhárek T; Vanochová A; Plank L
    Cesk Patol; 2011 Jul; 47(3):115-7. PubMed ID: 21887928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK2 exon 14 deletion in patients with chronic myeloproliferative neoplasms.
    Ma W; Kantarjian H; Zhang X; Wang X; Zhang Z; Yeh CH; O'Brien S; Giles F; Bruey JM; Albitar M
    PLoS One; 2010 Aug; 5(8):e12165. PubMed ID: 20730051
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.